Merck reports Q3 non-GAAP loss of $0.13, raises 2026 revenue outlook

Merck reported a Q3 2026 non-GAAP loss per share of $0.13, beating the $0.26 loss expected, driven by a $2.31 per-share charge related to its acquisition of Terns Pharmaceuticals. The company raised its 2026 revenue outlook to $66.3-67.3 billion but lowered adjusted EPS guidance to $2.66-2.76.

Detected & updated continuously · Source: Nebula